NCT02598388View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

PHASE2CompletedINTERVENTIONAL
Enrollment

578

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

December 12, 2018

Study Completion Date

December 12, 2018

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

Ad26.ZEBOV

One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).

BIOLOGICAL

MVA-BN-Filo

One 0.5 mL IM injection of (1x10\*8 infectious units).

BIOLOGICAL

Placebo

One 0.5 mL IM injection of 0.9 percent (%) saline.

Trial Locations (7)

Unknown

Silver Spring

Kericho

Kisumu

Maputo

Abuja

Mbeya

Kampala

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02598388 - Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo | Biotech Hunter | Biotech Hunter